SCHEMBL24329193

SCHEMBL24329193

CN1CCC(c2ccc3c4c(cccc24)C(=O)N3C2CCC(=O)NC2=O)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 18/20 0.53
DDB1 Q16531 12/20 0.53
IKZF3 Q9UKT9 2/20 0.53
ALDH1A1 P00352 1/20 0.53
CHRM2 P08172 1/20 0.53
OPRM1 P35372 1/20 0.53
CYP1A2 P05177 1/20 0.53
TSHR P16473 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
BCL2L11 O43521 1/20 0.48
BCL2 P10415 1/20 0.48
MCL1 Q07820 1/20 0.48
TNF P01375 1/20 0.48
IL1B P01584 1/20 0.48
TBXA2R P21731 1/20 0.48
IKZF1 Q13422 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24329195 0.96 CRBN (0.52) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29610310 0.90 CRBN (0.48) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315883 0.90 CRBN (0.48) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL23541054 0.88 CRBN (0.55) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29583008 0.88 CRBN (0.55) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29532776 0.87 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315885 0.87 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29583097 0.85 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL23541282 0.85 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL25034859 0.84 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024055112-A1 BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2024-03-21 WO disclosed
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed